Oxford BioTherapeutics
Phase 1At Oxford BioTherapeutics, we are dedicated to pioneering the next generation of oncology treatments through targeted therapies, including Antibody-Drug Conjugates (ADC), Immuno-oncology, T-Cell Engagers (TCE), and radiopharmaceuticals.
Founded
2008
Focus
AntibodiesBiologics
About
At Oxford BioTherapeutics, we are dedicated to pioneering the next generation of oncology treatments through targeted therapies, including Antibody-Drug Conjugates (ADC), Immuno-oncology, T-Cell Engagers (TCE), and radiopharmaceuticals.
Funding History
3Total raised: $99.5M
Series C$48MSamsara BioCapitalMar 15, 2022
Series B$30MM VenturesJun 15, 2020
Series A$21.5MBoehringer Ingelheim Venture FundJan 15, 2018
Company Info
TypePrivate
Founded2008
LocationBasel, Switzerland
StagePhase 1
Contact
SIMILAR COMPANIES
3Brain
Pre-clinical · Zug
Baxiva
Pre-clinical · Zug
AC Bioscience
Pre-clinical · Lausanne
Abrinca Genomics
Pre-clinical · Zurich
AdipoGen
Pre-clinical · Liestal
Is this your company?
Claim your profile to update information, add pipeline data, and connect with investors.
Claim profile